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ABSTRACT
Introduction: Development of higher
standards for diabetes care is a core element of
coping with the global diabetes epidemic.
Diabetes guidelines are part of the approach to
raising standards. The epidemic is greatest in
countries with recent rises in income from a low
base. The objective of the current study was to
investigate the availability and nature of locally
produced diabetes guidelines in such countries.
Methods: Searches were conducted using
Medline, Google, and health ministry and
diabetes association websites.
P. Home (&)
Institute of Cellular Medicine, The Medical School,
Newcastle University, Framlington Place,
Newcastle upon Tyne NE2 4HH, UK
e-mail: philip.home@ncl.ac.uk
J. Haddad
Division of Endocrinology, Department of Internal
Medicine, Prince Hamazah Hospital, Hani Rifai 34,
Amman, Jordan
Z. A. Latif
Bangladesh Institute of Research and Rehabilitation
in Diabetes, Endocrine & Metabolic Disorder
(BIRDEM), 122, Kazi Nazrul Ave. Shahbag, Dhaka,
Bangladesh
P. Soewondo
Faculty of Medicine University Indonesia, Jl
Salemba Raya no 6 Jakarta, Pusat 10430, Indonesia
Y. Benabbas
Department of Medicine, University Hospital
of Constantine, Cite´ Geric bat.9 Ain-Smara,
25140 Constantine, Algeria
L. Litwak
Diabetes and Metabolism Section, Hospital Italiano
de Buenos Aires, Lafinur 3050 Piso 88 Dpto. 2,
(1425), Buenos Aires, Argentina
S. Guler
Ankara Numune Training and Research Hospital,
Sıhhiye, Ankara 06100, Turkey
J.-W. Chen
Novo Nordisk, International Operations A/S,
Thurgauerstrasse 36, 8050 Zurich, Switzerland
A. Zilov
Department of Endocrinology, First Moscow State
Medical University, 1 Pogodinskaya Street, Office
622, Moscow 119435, Russia
Enhanced content for this article is
available on the journal web site:
www.diabetestherapy-open.com
123
Diabetes Ther (2013) 4:91–102
DOI 10.1007/s13300-013-0022-2
Results: Guidelines were identified in 33 of 75
countries outside North America, western
Europe, and Australasia. In 25 of these 33
countries, management strategies for type 1
diabetes were included. National guidelines
relied heavily on pre-existing national and
international guidelines, with reference to
American Diabetes Association standards of
medical care and/or other consensus
statements by 55%, International Diabetes
Federation by 36%, European Association for
the Study of Diabetes by 12%, and American
Association of Clinical Endocrinologists by 9%.
The identified guidelines were generally
evidence-based, though there was some use of
secondary evidence reviews, including other
guidelines, rather than original literature
reviews and evidence synthesis. In type 1
diabetes guidelines, the option of different
insulin regimens (mostly meal-time ? basal or
premix regimens) was recommended depending
on patient need. Type 2 diabetes guidelines
either recommended a glycosylated hemo-
globin target of \7.0% (\53 mmol/mol) (70%
of guidelines) or \6.5% (\47 mmol/mol) (30%
of guidelines) as the ideal glycemic target. Most
guidelines recommended a target fasting plasma
glucose that fell within the range of
3.8–7.2 mmol/L. Most guidelines also set a 2-h
post-prandial glucose target value within the
range of 4.0–8.3 mmol/L.
Conclusion: While only a first step in achieving
a high quality of disease management, national
guidelines of quality and with fair consistency
of recommendations are becoming prevalent
globally. A further challenge is implementation
of guidelines, by integration into local care
processes.
Keywords: Diabetes; Fasting plasma glucose;
Guidelines; Non-western countries; Local care;
Post-prandial glucose; Type 1 diabetes; Type 2
diabetes
INTRODUCTION
The worldwide prevalence of diabetes was
estimated as 366 millions in 2011 (8.3% of the
population), and is predicted to rise to 552
millions (9.9%) by 2030 [1]. The total number
of excess deaths due to diabetes in 2011 in the
20–79 age group was estimated to be nearly 4.6
million (6.8% of global deaths) [2]. According to
forecasts, diabetes will have an increasing impact
on years of life lost due to premature death and
disability, shifting from the eleventh to seventh
most common cause of death by 2030 [3]. In
addition, diabetes has an important economic
burden; globally, 12% of health expenditure was
expected to be spent on diabetes in 2010 [4]. The
greatest increases in diabetes prevalence have
occurred in countries in economic transition, in
particular in the Middle East, sub-Saharan Africa,
China, and the Indian subcontinent [5]. This has
the potential to put severe strain on healthcare
systems in these countries [6–8].
There are a number of internationally
recognized guidelines, algorithms, and
position statements for the diagnosis, control,
and management of diabetes [9–13], covering a
range of different components of diabetes care,
often with an emphasis on glucose-lowering
therapies. These factors together with updates
make use and implementation of the latest
versions of the guidelines desirable but
challenging [14–18]. However, implementation
of guidelines for the management of diabetes
has beneficial effects for the individual with
diabetes, including a significant reduction in
complications associated with diabetes, such as
hospitalizations [19].
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Despite the increasing burden of disease,
measures of the use of guidelines repeatedly
show poor implementation of, and adherence
to, current recommendations [20, 21]. The
quality of disease management is reduced
because there is a gap between guideline
recommendations and clinical practice [21].
Amongst reasons for non-implementation of
guidelines may include poor access to the
guidelines for clinicians, and the reduced
access to healthcare resources of the target
population [22].
Development and implementation of local
standards of care quality to ensure ‘local
ownership’ are considered important in
securing a basis for guideline implementation
[23]. Indeed, implementation of diabetes
clinical practice guidelines have resulted in
increases in the percentage of patients
reaching glycosylated hemoglobin (HbA1c) and
low-density lipoprotein (LDL) targets [23, 24].
Compliance with national standards of care has
been shown to make a substantial difference in
the control of chronic diseases, such as diabetes
[21, 25].
The purpose of the current study was to
identify the establishment of national
guidelines for the management of diabetes for
a range of countries where income is changing
from a low base, to investigate the coverage of
these local guidelines, and to discuss the
differences between different local guidelines
and between local and international guidelines.
METHODS
Search Strategy and Terms
Searches were conducted using Medline,
Google, and health ministry and diabetes
association websites. Medline searches used
the term ‘diabetes’ combined with ‘guideline’
or ‘recommendations’ or ‘consensus’, and the
country names of non-western countries
(outside North America, western Europe, and
Australasia) available from International
Diabetes Federation (IDF) member associations
list. Countries included Albania, Algeria,
Argentina, Azerbaijan, Bangladesh, Belarus,
Bolivia, Brazil, Cameroon, Central African
Republic, Chad, Chile, China, Colombia,
Costa Rica, Cuba, Dominican Republic,
Ecuador, Egypt, El Salvador, Estonia, Ethiopia,
Gambia, Guatemala, Honduras, Hong Kong,
India, Indonesia, Iran, Iraq, Israel, Ivory Coast,
Jordan, Kazakhstan, Kenya, Kuwait, Lebanon,
Libya, Lithuania, Malaysia, Maldives, Mauritius,
Mexico, Morocco, Nepal, Nicaragua, Nigeria,
Pakistan, Panama, Paraguay, Peru, Philippines,
Puerto Rico, Qatar, Russia, Rwanda, Saudi
Arabia, Senegal, Seychelles, Singapore,
Slovakia, Slovenia, South Africa, South Korea,
Syria, Taiwan, Tanzania, Thailand, Tunisia,
Turkey, United Arab Emirates, Uganda,
Ukraine, Uruguay, and Venezuela, or their
regions (e.g., South America). Countries with
guidelines were grouped into four regions:
North Africa and Middle East, East and South
Asia, Central and South America, and ‘Other’
(Table 1). Google searches were made using
similar terms and combinations of terms to
those listed above. Google searches were also
run for ministry of health and diabetes
association websites in the individual
countries listed above, and those websites
searched for guidelines.
Inclusion Criteria and Translation
Identified guidelines were retained for further
analysis if they made recommendations for use
or titration of glucose-control therapies in type
1 or type 2 diabetes; or if they contained
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guidelines specific for control of post-prandial
glucose (PPG) levels or hypoglycemia; or special
groups, such as children, the elderly, or those
with complications. Guidelines were not
included if they only dealt with lifestyle
management, patient education, or
psychological care; or were only concerned
with screening and diagnosis; only concerned
with non-glucose cardiovascular risk factors; or
were specific to monitoring of glucose control,
or specific to management of specific
complications, including preventative foot
care. If more than one guideline was available
from any country, the authors relied on the
knowledge of a local Novo Nordisk clinical
advisor to advise on the main guideline in
clinical use.
Guidelines that were not in English were
translated using Google translate, including
translations from Spanish, Portuguese, French,
Indonesian, Hebrew, and Thai. Some guidelines
could not be translated using the Google
translate program and in these instances the
guidelines were translated and tabulated by a
local clinical advisor who was a native speaker,
kindly provided by the local Novo Nordisk
affiliate.
Analysis
The following parameters were assessed in the
national guidelines: the source of the guidelines,
e.g., whether from a national society or from
the ministry of health; year of most recent
guideline; year of previous guidelines; whether
national guidelines were specifically based
on international guidelines or consensus
documents; whether specific recommendations
for pediatric populations, the elderly, and
gestational diabetes were present; post-prandial
control; management of hypoglycemia;
recommended first-, second-, and third-line
insulin treatment for type 1 diabetes (if any);
and recommended first-, second-, and third-line
therapies for type 2 diabetes (if any).
This article does not contain any studies
with human beings or other animals performed
by any of the authors.
Table 1 Breakdown of non-western countries with identifiable national guidelines by region
North Africa and Middle East
(n5 11)
East and South Asia
(n5 9)
Central and South America
(n5 5)
Other
(n5 8)
Algeria Bangladesh Argentina Belarus
Egypt China Brazil Kazakhstan
Iraq India Chile Israel
Jordan Indonesia Mexico Kenya
Lebanon Malaysia Venezuela Russia
Libya Singapore Turkey
Morocco South Korea Ukraine
Saudi Arabia Taipei South Africa
Syria Thailand
Tunisia
United Arab Emirates
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RESULTS
National guidelines for the management of
glucose control were not identified for 42
(56%) of the 75 countries; one or more
guidelines were available for 33 countries
(Table 1). The year of the latest national
guideline (2003–2010) was available for 31
(94%) of the 33 countries. Twenty-one (68%)
of 31 countries in this group had developed or
updated national guidelines since 2008. The
identified guidelines were generally evidence-
based, though there was some use of secondary
evidence reviews, including other guidelines,
rather than original literature reviews and
evidence synthesis.
Origin of National Guidelines
National guidelines were developed or
supported by national ministries of health in
36 % of countries, national diabetes societies/
associations in 58 % of countries, and both the
ministry of health and national diabetic
association in 6 % of countries.
Specific mention was made to source other
national or international guidelines in the
recommendations from 26 of 33 (79%)
countries. The World Health Organization
(WHO) definition of diabetes was mentioned
by ten (30%) countries, reference to the
American Diabetes Association (ADA)
standards of medical care and/or other
consensus statements was made by 18 (55%)
countries, IDF guidelines by 12 (36%) countries,
European Association for the Study of Diabetes
(EASD) consensus statement by four (12%)
countries, Association Latin America de
Diabetes (ALAD) guidelines by 1 (3%) country,
and American Association of Clinical
Endocrinologists (AACE) guidelines by three
(9%) countries.
Type 1 Diabetes
National guidelines for type 1 diabetes, or
provision for type 1 diabetes in broader
guidelines, were available for 25 of 33 (76%)
countries (Table 2). Sixteen of the 25 countries
(64%) that provided recommendations for first-
line insulin therapy suggested the option of
more than one type of regimen according to
individual requirements. Meal-time ? basal
insulin regimens and premixed insulin were
recommended in 60% of guidelines as first-line
treatment options. Insulin analogs, such as the
rapid-acting insulins (aspart, lispro), the long-
acting insulins (glargine, detemir), and
premixed insulin analogs, were specifically
mentioned as available options in 18 of 25
(72%) national guidelines.
Nine of the 25 (36%) country guidelines
specified a second-line insulin regimen.
Intensification with a meal-time ? basal
regimen was specified by four countries, use of
insulin pump therapy was specified by two
countries, and three countries suggested more
than one option for intensification. Two
countries mentioned a third-line management
option of intensification of meal-time ? basal
insulin therapy.
Targets for Glycemic Control
Targets for glycemic control varied between
guidelines. However, all guidelines either
recommended an HbA1c target of \7.0%
(\53 mmol/mol) (70% of guidelines) or \6.5%
(\47 mmol/mol) (30% of guidelines) as the
ideal glycemic target (Table 3). Most (89%)
guidelines recommended a target fasting
plasma glucose (FPG) that fell within the range
of 3.8–7.2 mmol/L, and the remaining
guidelines set a FPG target of \8.0 mmol/L.
Most (68%) guidelines also set a 2-h PPG target
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value somewhere within the range of
4.0–8.3 mmol/L and the remaining guidelines
set a PPG target of either \8.8 mmol/L or
\10.0 mmol/L.
First-line Medication Therapy for Glucose-
Lowering in Type 2 Diabetes
Overall, 33 countries had national guideline
recommendations for type 2 diabetes (Table 2).
Most countries (67%) recommended lifestyle
changes either before or in conjunction with
beginning therapy with oral glucose-lowering
drugs (OGLDs).
In only one country (Mexico) metformin was
not formally endorsed as first-line therapy, but
this guideline made provision for use of any oral
agent. In South Korea, first-line options
included metformin, a glucagon-like peptide-1
(GLP-1) receptor agonist, a dipeptidyl peptidase-
Table 2 Non-western countries with national guidelines for type 1 diabetes or provision for type 1 diabetes within broader
diabetes guidelines, and those with guidelines for type 2 diabetes
North Africa
and Middle East
East and South Asia Central and
South America
Other
Type 1 diabetes (n) 7 9 4 5
Algeria Bangladesh Argentina Kazakhstan
Egypt China Brazil Kenya
Iraq India Chile Russia
Lebanon Indonesia Venezuela Turkey
Syria Malaysia Ukraine
Tunisia Singapore
United Arab Emirates South Korea
Taipei
Thailand
Type 2 diabetes (n) 11 9 5 8
Algeria Bangladesh Argentina Belarus
Egypt China Brazil Kazakhstan
Iraq India Chile Israel
Jordan Indonesia Mexico Kenya
Lebanon Malaysia Venezuela Russia
Libya Singapore Turkey
Morocco South Korea Ukraine
Saudi Arabia Taipei South Africa
Syria Thailand
Tunisia
United Arab Emirates
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4 (DPP-4) inhibitor, an alpha-glucosidase
inhibitor, or a sulfonylurea. In Russia, first-line
options included metformin, a GLP-1 receptor
agonist, or a DPP-4 inhibitor, especially if
metformin is poorly tolerated. In all other
countries (94%), metformin was recommended
as the first-line treatment. However, in 48% of
countries who recommended beginning OGLD
therapy with metformin, provision was also
made for metformin to be used in combination
with either another oral agent therapy if HbA1c
was [8.0% ([64 mmol/mol), or with insulin if
HbA1c was [9.0% ([75 mmol/mol).
Specific recommendations for non-obese,
weight-unspecified, or metformin-intolerant
people were available in guidelines from 26
(79%) countries. Alternatives included
sulfonylureas (77% of countries),
thiazolidinediones (35%), glinides (19%), alpha–
glucosidase inhibitors (27%), GLP-1 receptor
agonists (19%), or DPP-4 inhibitors (35%).
Second- and Third-line Medications
for Glucose-lowering in Type 2 Diabetes
In most instances, second-line therapy was
recommended when blood glucose control was
not maintained at a target HbA1c level of
\53 mmol/mol (\7.0%), but some guidelines
suggested up-titration if above 47 mmol/mol
(6.5%) or [42 mmol/mol ([6.0%). In many
guidelines, an interval of 3–6 months was
suggested after starting metformin or other
medication before a further medication was
added. Most recommendations were for a
second oral agent rather than an injectable;
usually (in 66% of guidelines) addition of a
sulfonylurea to metformin. Some guidelines
also suggested alternatives to sulfonylurea for
use as a second drug in combination therapy,
including thiazolidinediones, DPP-4 inhibitors,
or alpha-glucosidase inhibitors. GLP-1 receptor
agonists were suggested as a second-line
combination option by only 2 of 32 (6%)
guidelines. In some countries (46%) when
HbA1c was [9.0% ([75 mmol/mol), starting
with basal insulin plus one OGLD was
recommended as an option.
Twelve of 32 (38%) guidelines suggested that
insulin therapy could be considered second-line
in conjunction with metformin or another oral
agent. The type of insulin was unspecified in
42% of guidelines, but in 42% basal insulin as a
single insulin was an option, and in 25%
premixed insulin was an option.
Third-line therapy was specifically
mentioned in 30 guidelines, with an
additional oral agent suggested as an option in
40% of these. Insulin therapy was suggested as
an option by 25 of 30 (83%) guidelines. Of these
Table 3 Type 2 diabetes glycemic control targets across regions
Region Glycemic target
HbA1c <6.5%
(<48 mmol/mol) (%)
HbA1c <7.0%
(<53 mmol/mol) (%)
FPG
(mmol/L)
PPG
(mmol/L)
North Africa and Middle East 30 70 4.4 to\7.8 5.5 to\10.0
East and South Asia 43 57 4.4 to 8.0 4.4 to\10.0
Central and South America 20 80 3.8 to 7.2 7.7 to\10.0
Others 0 100 3.9 to\7.0 4.0 to 8.0
HbA1c glycosylated hemoglobin, FPG fasting plasma glucose, PPG post-prandial glucose
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guidelines, the type of insulin was not specified
in 44% of guidelines (e.g., insulin initiated
according to the patients’ needs), beginning
with basal insulin was recommended in 44%,
with premixed insulin in 32%, long-acting in
12%, and 20% of guidelines allowed initiation
with more than one specified insulin regimen
(e.g., initiate with long-acting or long-acting
plus rapid-acting or premixed).
Guidelines from 22 of 33 (67%) countries
made specific provision for post-prandial blood
glucose control within their diabetes guidelines.
There was little regional variation in these
recommendations, with eight of 11 North
African and Middle Eastern countries, six of
nine South and East Asian countries, three of
five Central and South American countries, and
five of eight other countries suggesting this
measure should receive attention. Four of these
countries suggested the use of alpha-glucosidase
inhibitors to improve post-prandial blood
glucose control (Lebanon, Libya, Mexico,
Tunisia), while eight suggested rapid-acting
(meal-time) insulin analogs (Saudi Arabia,
Malaysia, Singapore, South Korea, Brazil,
Mexico, Belarus, Kazakhstan).
Hypoglycemia Treatment Guidelines
Guidelines from 23 of 33 (70%) countries
included recommendations for the
management of hypoglycemia. While this was
mainly for the use of oral carbohydrate for
symptomatic hypoglycemia, the use of
intramuscular or subcutaneous glucagon was
the most widely recommended intervention for
severe hypoglycemia.
Special Groups
Information was available for special groups of
people with diabetes in guidelines from 31 of the
33 countries. Of these, 23 countries (74%) had
recommendations for the management of
gestational diabetes, 16 of 31 (52%) for the
elderly, and 21 of 31 (68%) for pediatric patients.
DISCUSSION
The development of insulin analogs and GLP-1
receptor agonists, and the increase in the
number of available OGLDs have increased the
number of glucose-lowering therapy options for
people with type 1 or type 2 diabetes [26–28],
while management of other conditions
(elevated lipids and blood pressure, or
complications) has also evolved [26–28]. Some
clinicians find authoritative guidelines useful in
giving direction to the appropriate
management pathways, while others use them
to endorse and review their own practice in the
diverse areas of diabetes care [12]. While
national and international guidelines,
algorithms, and position statements on the
management of diabetes, and more specifically
on glucose-lowering medication, published by
ADA, IDF, EASD, and ALAD, together with some
high-quality national guidelines, seek to address
the clear medical need for guidance in the
management of diabetes, these may not meet
the needs of local populations at the national or
provincial level in non-western countries.
Not surprisingly, the national guidelines
identified in this review relied heavily on pre-
existing international guidelines. In most
countries, the latest version of national
guidelines was published before 2012 and
consequently could not contain reference to
the latest position statement from ADA/EASD
[17]. This may be problematic as there was
significant change between 2009 and 2013 in
glucose-lowering treatment options. Also
endorsed in the new statement from ADA/
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EASD was the approach to individualization of
medical decision-making [17]. Ideas on
individualizing management, and an approach
to variation in provision of care according to
available resources, were espoused by the 2005
IDF type 2 diabetes guideline, but changes were
needed for the 2012 revision in light of new
therapy options [16]. Also, the ADA standards in
medical care is updated annually to include the
latest available information on managing
diabetes [18] while national guidelines are
updated less frequently and may not reflect all
new therapy options as they become available.
As this study focussed on adults, the authors
have not included international pediatric type 1
diabetes guidelines, such as those from the
International Society for Pediatric and
Adolescents Diabetes (ISPAD), in the present
analysis [29]. However, most national
guidelines for type 1 diabetes in adults
emphasized the importance of meeting the
needs of individual patients when beginning
and modifying insulin therapy, with meal-
time ? basal insulin regimens most commonly
cited as being likely to meet individual
requirements, especially for post-prandial
blood glucose control and for reducing the risk
of hypoglycemia. Insulin analogs, such as the
rapid-acting insulins (aspart, lispro), biphasic
insulins based on these, and the long-acting
insulins (glargine, detemir), were specifically
mentioned as available options in 18 of 25
(72%) national guidelines for type 1 diabetes.
In the management of hyperglycemia in type
2 diabetes, most national guidelines were in
agreement with international guidelines in
their recommendation of metformin as the
treatment of choice for first-line therapy,
especially in obese patients, though the option
of combination with another OGLD or insulin
was addressed in 48% of countries. Likewise,
most national guidelines acknowledged
sulfonylureas as a first-line treatment option in
people who were not obese and for those who
could not tolerate metformin. This was in
general agreement with recommendations in
IDF guidelines and ADA statements on the use
of sulfonylureas if and when metformin is
insufficient, is not tolerated, or in people who
are not overweight [16–18].
Differences do, however, appear in both
national and international recommendations as
to the use of second-line therapies if glucose-
control targetsarenotattainedwithin3–6 months
or if subsequent deterioration of glucose control
occurs. While the cost-effective sulfonylureas are
most commonly recommended, some guidelines
also made provision for the addition of other
OGLDs drugs, including thiazolidinediones, DPP-
4 inhibitors, and alpha-glucosidase inhibitors.
Many guidelines (12 of 33) also suggest the
option of injectables, GLP-1 receptor agonists,
and insulin as a second-line therapy options, as
does the recent position statement from the ADA/
EASD group [17].
A problem with international guidelines is
that they can give so many alternative treatment
options that the less specialist practitioner may
fail to make the optimum treatment
recommendations for each type of patient. In
addition, complex regimens may lead to payors
agreeing to reimburse the cheapest available
option(s). National guidelines that allow
multiple treatment options but discuss the
benefits and weaknesses of individual classes of
glucose-lowering therapies may then be closer to
assisting health-care professionals in meeting the
medical needs of people with type 2 diabetes.
Another consideration is whether provision
is made in national guidelines for specific
clinical situations, post-prandial blood glucose
control, and hypoglycemia. Guidelines from
67% of countries in the study made some
provision for PPG control, with use of a rapid-
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acting insulin as part of a meal-time ? basal
insulin regimen the most common
recommendation, and an alpha-glucosidase
inhibitor was recommended in some
guidelines. Guidelines from 70% of countries
made provision for hypoglycemia.
A limitation of the current study is that it has
not been comprehensive in the inclusion of all
available national guidelines for all the countries,
but has specifically focussed on treatment
guidelines, which may have introduced bias
into the final analysis. A further limitation was
that some national guidelines may have been
inadvertently missed because they were not
freely available on the internet or were
restricted to a non-English website. Some
countries may also have one or more national
guidelines that they refer to. Furthermore, the
study had to rely on translation of guidelines
from the original language into English for many
countries, and this may have led to the inclusion
of inaccuracy or inconsistencies in the analysis.
For guidelines that could not be translated using
Google translation, the accuracy of the data
depended on the interpretation of a local
clinical advisor provided by Novo Nordisk who
translated the guidelines from the native
language. Also, the study did not include
guidelines for special groups, such as
recommendations for the management of
diabetes during Ramadan [30–32]. However, the
authors note that guidelines on the management
of diabetes during Ramadan stress the
importance of individualizing treatment to
meet the patient’s needs [30–32].
CONCLUSION
In conclusion, national guidelines were
identified for 33 out of 75 (44%) lower income
countries, of which 76% also had guidelines for
type 1 diabetes. Two-thirds of countries with
national guidelines for type 2 diabetes had
made the latest version of their guidelines
available after 2008, enabling the latest
treatment options to be included. Given that,
the consensus algorithms developed by ADA/
EASD have been criticized because they were
based mostly on expert opinion rather than on
an evidence-based process [26, 30]. Therefore, it
is notable that many national guidelines seem
now to have adopted a more evidence-based
approach. Furthermore, with regular updating
to reflect the rapid pace of change in the
management of type 2 diabetes, this suggests
that quality national guidelines may benefit a
wider international population of people with
diabetes.
However, establishment of national
guidelines is only the first step in achieving a
high quality of disease management and more
efforts need to be made for clinicians and
patients to adhere to the recommendations of
national guidelines, since glycemic control is
still poor in the countries where this study was
conducted.
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